All In Biotech

Drug Trial Radar · NCT00692770

Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation.

Last checked: Nov 20, 2026Latest source record: Aug 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,114 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,114

Actual

Start

Aug 15, 2008

Primary completion

Nov 29, 2013

Study completion Nov 28, 2014

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jun 6, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of Hepatocellular Carcinoma (HCC) after potentially curative treatment (surgical resection or local ablation).

Conditions

  • Carcinoma, Hepatocellular

Interventions

  • Nexavar (Sorafenib, BAY43-9006)Drug

    Sorafenib 400 mg twice daily (BID)

  • PlaceboDrug

    Placebo 2 tablets twice daily (BID)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence Free Survival (RFS) by Independent AssessmentTime frame: From randomization up to 4 years or until disease recurrence whichever came first

Locations

199 sites in 28 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    San Francisco, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Miami, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Louisville, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Burlington, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    New York, New York

  • Site not named

    Cleveland, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

  • Providence Portland Medical Center

    Portland, Oregon

  • Site not named

    Portland, Oregon

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Houston, Texas

  • Site not named

    Richmond, Virginia

  • Site not named

    Seattle, Washington

  • Site not named

    Seattle, Washington

  • Site not named

    Pilar, Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Rosario, Santa Fe Province, Argentina

  • Site not named

    Camperdown, New South Wales, Australia

  • Site not named

    Randwick, New South Wales, Australia

  • Site not named

    Brisbane, Queensland, Australia

  • Site not named

    Heidelberg, Victoria, Australia

  • Site not named

    Melbourne, Victoria, Australia

  • Site not named

    Innsbruck, Austria

  • Site not named

    Linz, Austria

  • Site not named

    Vienna, Austria

Showing 40 of 199 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.